Remove

PICOSSIBLE (0.4.1)
Approved for use through 07/10/2008 (0.40) 051-001.

U.S. Peletr and Trisdemaid Office; U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination under its ordinaries and soft office ordinaries.

	Application Number		
	Filing Date		
INFORMATION DISCLOSURE	First Named Inventor	Dario	Milana
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	06CIN018

HI C DATENTO

					Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee or Applicant		Releva	Columns,Lines where ant Passages or Relevar s Appear	
	1	5090698		1992-02-25	Kleinfelter			
	2	5616089		1997-04-01	Miller			
	3	5830081		1998-11-03	Kitahara			
	4	6190266		2001-02-20	Pamias			
If you wis	h to a	dd additional U.S. Pater	nt citatio	n information p	lease click the	Add button.		Add
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where ant Passages or Relevar s Appear
	1							
If you wis	h to a	d additional U.S. Publi:	shed Ap	plication citation	n information	please click the Ado	d button	Add
·				FOREIGN PA	TENT DOCUM	MENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DIGGI COURT					Date						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			First Named Inventor Dar			Dani	o Milana				
			Art Ur	nit		_					
			Examiner Name								
				Attorn	ey Doc	ket Numb	er	06CIN018	06CIN018		
	1										
If you wish	n to a	dd additional Foreign P	atent Doo	ument	citation	information	on ple	ase click the Add buttor	n Add		
			NON	-PATE	NT LITE	RATURE	DOC	UMENTS	Remove		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (nitials* No look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.										Тs	
	1										
If you wish to add additional non-patent literature document citation information please click the Add button Add											

Application Number

EXAMINER SIGNATURE

Examiner Signature | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See first Ooder of USPTO Platest Documents at search USETO.QQU'er aNEICP 961.64. Totter office that assess the document, by the bro-later code (NPD) Standard 51.3). "For Japanese patient counters, the oricidation of the year of the right of the Emperor range precess the sent an inventor of the patient bready."

**Yard of Gourrent by the appropriate symbols as enducated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if Emplish targuages restration in statistics."

Application Number Flang Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Flang Date First Number I Date Milana Art Unit Examiner Name Attorney Docket Number I 090/N018

CERTIFICATION STATEMENT

Please see	37	CER 1	97	and	1 08	to make	the.	annror	viota	coloction	e)-	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, nd, to the knowledge of the person signing the cartification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 1976(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Franco A. Serafini/	Date (YYYY-MM-DD)	2006-10-12
Name/Print	Franco A. Serafini	Registration Number	52207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.